Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Cisco Systems Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Cisco Systems Inc trades at $117.19 (market cap $461.50B). The key difference: Cisco Systems Inc is far larger — about 57.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Cisco Systems Inc pays a 1.43% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CSCO | |
|---|---|---|
Market Cap | $8.04B | $461.50B |
Sector | Health | Technology |
52-Week High | $339.75 | $130.00 |
52-Week Low | $241.71 | $66.20 |
Enterprise Value | $7.85B | $476.17B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Cisco Systems (CSCO) trades at $117.09, down 3.48% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Revenue for 2025 was $56.65 billion, with a net income margin of 19.69%. Recent news highlights Cisco's strategic AI and cybersecurity partnerships, positioning it for growth in the networking and security markets.
The outlook for CSCO is positive, supported by analyst consensus with a $130.38 price target and 52% buy ratings. Key opportunities include AI-driven security demand and solid cash flow. Risks involve competitive pressures and debt levels, with a debt-to-asset ratio of 22.97% in 2025. Investors should weigh strong fundamentals against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
